{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:12:28Z","timestamp":1772104348328,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Peripheral neuralgia is a chronic pain syndrome resulting from peripheral nerve damage and has been increasingly linked to certain drugs, leading to drug-induced peripheral neuropathy (DIPN). While the neurotoxic potential of many drugs has been recognized, the gender-specific patterns of DIPN remain insufficiently studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify potential drug safety signals associated with DIPN and explore gender-based differences in risk using real-world pharmacovigilance data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2024. Disproportionality analysis (DPA), specifically Reporting Odds Ratio (ROR), was applied to detect associations between drugs and DIPN. Drug and adverse event terms were standardized using RxNorm and MedDRA dictionaries. Weibull distribution modeling was employed to analyze time-to-onset (TTO) characteristics of high-risk drugs in male and female populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 21,609 adverse event reports of DIPN were analyzed, showing a continuous increase in reporting over two decades. Seventy-two drugs were identified as having potential DIPN risk signals, with 25 drugs showing strong associations after statistical adjustments. Among them, adalimumab, ciprofloxacin, and lenalidomide had the highest number of reports. Eighteen drugs presented new risk signals not previously mentioned in official drug labeling. Gender-specific analysis revealed 49 risk drugs in females, 32 in males, with 23 drugs overlapping. Time-to-onset analysis showed most adverse events occurred early in treatment, as indicated by Weibull shape parameters (\u03b2 &amp;lt; 1) for all major drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study revealed novel and sex-specific DIPN risk signals using large-scale real-world data. It highlights the importance of early monitoring of neurotoxic effects during drug treatment and provides strong support for implementing gender-sensitive pharmacovigilance strategies and individualized medication risk management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1628362","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:28:05Z","timestamp":1754630885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat"],"prefix":"10.3389","volume":"16","author":[{"given":"Xianyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.3390\/ijms150610479","article-title":"Estrogen rapidly enhances incisional pain of ovariectomized rats primarily through the G protein-coupled estrogen receptor","volume":"15","author":"An","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e54565","DOI":"10.7759\/cureus.54565","article-title":"Fluoroquinolones: neurological complications and side effects in clinical practice","volume":"16","author":"Anwar","year":"2024","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1264668","DOI":"10.3389\/fvets.2023.1264668","article-title":"Preclinical research in paclitaxel-induced neuropathic pain: a systematic review","volume":"10","author":"Bacalhau","year":"2023","journal-title":"Front. Vet. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","article-title":"An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms\/dissections disseminated by the food and drug administration and the european medicines agency","volume":"18","author":"Bennett","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms26062532","article-title":"Sex steroids and brain-derived neurotrophic factor interactions in the nervous system: a comprehensive review of scientific data","volume":"26","author":"de Assis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/bcp.14094","article-title":"Prescribing medicines to older people-how to consider the impact of ageing on human organ and body functions","volume":"86","author":"Drenth-Van Maanen","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.3390\/ijms23137191","article-title":"Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-\u03b1-Necroptosis pathway","volume":"23","author":"Duan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/j.pain.0000000000000775","article-title":"Individual differences in pain: understanding the mosaic that makes pain personal","volume":"158","author":"Fillingim","year":"2017","journal-title":"Pain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/187152711794653751","article-title":"Targeting TNF-\u03b1 to elucidate and ameliorate neuroinflammation in neurodegenerative diseases","volume":"10","author":"Frankola","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14534","article-title":"Adalimumab monotherapy or combination therapy with methotrexate in paediatric uveitis: data from the AIDA network uveitis registry","author":"Gaggiano","year":"2025","journal-title":"Clin. Exp. Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1574884714666190121154813","article-title":"Drug-induced peripheral neuropathy: a narrative review","volume":"15","author":"Jones","year":"2020","journal-title":"Curr. Clin. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10072-024-07813-0","article-title":"Predictors for quality of life improvement following rTMS treatment in neuropathic pain patients","volume":"46","author":"Lacroix","year":"2025","journal-title":"Neurol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/jpm13060965","article-title":"Sex- and gender-specific drug abuse dynamics: the need for tailored therapeutic approaches","volume":"13","author":"Marinelli","year":"2023","journal-title":"J. Pers. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.3390\/ijerph17113926","article-title":"Gender differences in medication use: a drug utilization study based on real world data","volume":"17","author":"Orlando","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12183","DOI":"10.3390\/ijms232012183","article-title":"Interferon Beta-1a versus combined interferon Beta-1a and oligodendrocyte-specific FGFR1 deletion in experimental autoimmune encephalomyelitis","volume":"23","author":"Rajendran","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00326","DOI":"10.1002\/brb3.326","article-title":"Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?","volume":"5","author":"Stettner","year":"2015","journal-title":"Brain Behav."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e16164","DOI":"10.1111\/ene.16164","article-title":"Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: a phase 1 study to identify the maximum tolerated dose","volume":"31","author":"Stino","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1000119","DOI":"10.4172\/2157-7609.1000119","article-title":"Sex differences in the expression of drug-metabolizing and transporter genes in human liver","volume":"3","author":"Yang","year":"2012","journal-title":"J. Drug Metab. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1628362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:28:06Z","timestamp":1754630886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1628362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":21,"alternative-id":["10.3389\/fphar.2025.1628362"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1628362","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1628362"}}